The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model

Sleep Medicine

Volumn 12, Issue 1, 2011, Pages 41-46

  Luo, Feifei ^a,b   Li, Chao ^a,c   Ondo, William G ^a   Xu, Pingyi ^b   Xie, Wenjie ^a   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Animal model; Augmentation; Dopamine agonist; Dopamine receptors; Iron; Pramipexole; Restless legs syndrome

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HOMOVANILLIC ACID; IRON; MONOAMINE; OXIDOPAMINE; PRAMIPEXOLE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; IRON DEFICIENCY; LOCOMOTION; LONG TERM CARE; LUMBAR SPINAL CORD; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; RESTLESS LEGS SYNDROME;

ANIMALS; BENZOTHIAZOLES; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; IRON; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; RECEPTORS, DOPAMINE; RESTLESS LEGS SYNDROME; SEROTONIN; SPINAL CORD;

EID: 78650300126     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2010.07.009     Document Type: Article

References (21)

1. Phillips B., Young T., Finn L., et al. Epidemiology of restless legs syndrome in adults. Arch Intern Med 2000, 160:2137-2147.
2. Allen R.P., Picchietti D., Hening W.A., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
3. Allen R.P., Earley C.J. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001, 18:128-147.
4. Hening W.A. Restless legs syndrome: a sensorimotor disorder of sleep/wake motor regulation. Curr Neurol Neurosci Rep 2002, 2:186-196.
5. Manconi M., Hutchins W., Feroah T.R., et al. On the pathway of an animal model for restless legs syndrome. Neurol Sci 2007, 28:S53-S60.
6. Ondo W.G., Zhao H.R., Le W.D. Animal models of restless legs syndrome. Sleep Med 2007, 8:344-348.
7. Earley C.J., Connor J.R., Beard J.L., et al. Abnormalities in CSF concentrations of ferritin and transferring in restless legs syndrome. Neurology 2000, 54:1698-1700.
8. Connor J.R., Boyer P.J., Menzies B.S., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61:304-309.
9. Gladwell S.J., Coote J.H. Inhibitory and indirect excitatory effects of dopamine on sympathetic preganglionic neurons in the neonatal rat spinal cord in vitro. Brain Res 1999, 818:397-407.
10. Levant B., McCarson K.E. D(3) dopamine receptors in rat spinal cord: implications for sensory and motor function. Neurosci Lett 2001, 303:9-12.
11. Ondo W.G., He Y., Le W.D. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 2000, 15:154-158.
12. Takado M., Li Z.K., Hattori T. Single thalamic dopaminergic neurons project to both the neocortex and spinal cord. Brain Res 1988, 455:346-352.
13. Skagerberg G., Lindvall O. Organization of diencephalic neurons projecting to the spinal cord in the rat. Brain Res 1985, 342:340-351.
14. Qu S., Le W.D., Zhang X., et al. Locomotion is increased in A11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol 2007, 66:383-388.
15. Zhao H.R., Zhu W., Pan T.H., et al. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res 2007, 85:1065-1076.
16. Becker P.M., Ondo W., Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology 1998, 51:1221-1223.
17. Montplaisir J., Nicolas A.R.D., Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999, 52:938-943.
18. García-Borreguero D., Allen P., Benes H., et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007, 22:476-484.
19. Jiang C.T., Wan X.H., He Y., et al. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol 2005, 191:154-162.
20. Brodeur C., Montplaisir J., Godbout R., et al. Treatment of restless legs syndrome and periodic leg movements during sleep with l-dopa: a double-blind, controlled study. Neurology 1988, 12:1845-1848.
21. Earley C., Allen R. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996, 19:801-810.